| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
|
Science
|
2007
|
32.68
|
|
2
|
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
|
N Engl J Med
|
2013
|
14.78
|
|
3
|
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
|
J Clin Oncol
|
2013
|
11.68
|
|
4
|
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
|
N Engl J Med
|
2014
|
10.91
|
|
5
|
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
|
Lancet
|
2008
|
10.74
|
|
6
|
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
|
Cancer Cell
|
2010
|
7.78
|
|
7
|
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
|
J Clin Oncol
|
2009
|
4.27
|
|
8
|
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
|
Lancet Oncol
|
2013
|
4.20
|
|
9
|
Management of non-small-cell lung cancer: recent developments.
|
Lancet
|
2013
|
3.51
|
|
10
|
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
|
Clin Cancer Res
|
2005
|
2.81
|
|
11
|
Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.
|
J Thorac Oncol
|
2007
|
2.15
|
|
12
|
Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.
|
J Thorac Oncol
|
2012
|
1.86
|
|
13
|
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.
|
J Cell Mol Med
|
2009
|
1.62
|
|
14
|
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer.
|
Clin Lung Cancer
|
2012
|
1.16
|
|
15
|
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung.
|
Cancer
|
2011
|
1.10
|
|
16
|
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells.
|
Invest New Drugs
|
2007
|
1.04
|
|
17
|
Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC.
|
J Cell Mol Med
|
2014
|
1.00
|
|
18
|
A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.
|
Cancer Chemother Pharmacol
|
2007
|
1.00
|
|
19
|
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.
|
Med Oncol
|
2005
|
0.96
|
|
20
|
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
|
J Clin Invest
|
2014
|
0.95
|
|
21
|
PARP inhibition in BRCA-mutated breast and ovarian cancers.
|
Lancet
|
2010
|
0.94
|
|
22
|
INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer.
|
BMC Cancer
|
2011
|
0.92
|
|
23
|
EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey.
|
J Thorac Oncol
|
2015
|
0.88
|
|
24
|
Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic review.
|
Clin Lung Cancer
|
2011
|
0.88
|
|
25
|
Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors.
|
J Thorac Oncol
|
2010
|
0.88
|
|
26
|
Management of hepatocellular carcinoma: beyond sorafenib.
|
Curr Oncol Rep
|
2012
|
0.87
|
|
27
|
First-line crizotinib in ALK-positive lung cancer.
|
N Engl J Med
|
2015
|
0.86
|
|
28
|
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
|
Asia Pac J Clin Oncol
|
2012
|
0.86
|
|
29
|
Epigenomic analysis of lung adenocarcinoma reveals novel DNA methylation patterns associated with smoking.
|
Onco Targets Ther
|
2013
|
0.85
|
|
30
|
Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer.
|
J Surg Oncol
|
2002
|
0.84
|
|
31
|
Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
|
Cancer Treat Rev
|
2012
|
0.83
|
|
32
|
Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization.
|
Radiology
|
2013
|
0.83
|
|
33
|
Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview.
|
Lung Cancer
|
2008
|
0.82
|
|
34
|
Reviewing the safety of erlotinib in non-small cell lung cancer.
|
Expert Opin Drug Saf
|
2010
|
0.81
|
|
35
|
[Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version].
|
Zhonghua Bing Li Xue Za Zhi
|
2013
|
0.80
|
|
36
|
Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients.
|
Cancer
|
2013
|
0.78
|
|
37
|
Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life.
|
Anticancer Drugs
|
2008
|
0.77
|
|
38
|
Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.
|
J Thorac Oncol
|
2006
|
0.77
|
|
39
|
Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung CANCER.
|
Chin J Cancer Res
|
2011
|
0.75
|
|
40
|
Piloting electronic self report symptom assessment - Cancer (ESRA-C) in Hong Kong: a mixed method approach.
|
Eur J Oncol Nurs
|
2010
|
0.75
|